| Literature DB >> 25695601 |
T Bose1, A Cieślar-Pobuda2, E Wiechec3.
Abstract
Ion channels are abundantly expressed in both excitable and non-excitable cells, thereby regulating the Ca(2+) influx and downstream signaling pathways of physiological processes. The immune system is specialized in the process of cancer cell recognition and elimination, and is regulated by different ion channels. In comparison with the immune cells, ion channels behave differently in cancer cells by making the tumor cells more hyperpolarized and influence cancer cell proliferation and metastasis. Therefore, ion channels comprise an important therapeutic target in anti-cancer treatment. In this review, we discuss the implication of ion channels in regulation of Ca(2+) homeostasis during the crosstalk between immune and cancer cell as well as their role in cancer progression.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25695601 PMCID: PMC4669790 DOI: 10.1038/cddis.2015.23
Source DB: PubMed Journal: Cell Death Dis Impact factor: 8.469
Figure 1Fluctuations of membrane potential during activation of immune cells. Ca2+ influx in lymphocytes depends on the gradient between the extracellular Ca2+ concentration (~1 mM) and the intracellular Ca2+ concentration (~0.1 μM) as well as the electrochemical gradient established by K+ channels (specifically, Kv1.3, Kca3.1 and partially by K2P channels) and the Na+-permeable channel TRPM4. CRAC channels are activated upon the engagement of antigen receptors (i.e., TCRs, BCRs). This is mediated through the activation of PLCγ, the production of IP3 and the release of Ca2+ from ER Ca2+ stores. The subsequent activation of STIM1 and STIM2 results in the opening of ORAI1 CRAC channels and SOCE. Sustained Ca2+ entry through CRAC channels leads to the activation of Ca2+-dependent enzymes and transcription factors, including calcineurin and NFAT.[28] Additionally, P2X receptors (e.g., P2X4 and P2X7) are non-selective Ca2+ channels activated by extracellular ATP mediating Ca2+ influx in order to augment SOCE-mediated activation of signaling molecules (according to Launay P, 2004; Feske S, 2012). Abbreviations: TCR, T cell receptor; PLCγ1, phospholipase Cγ1; NFAT, nuclear factor of activated T cells; CRAC, calcium release-activated channels; STIM1/2, stromal interaction molecule 1/2; SOCE, store-operated calcium entry; P2X, purinergic receptor 2X
The role of distinct ion channels in cancer development and progression
| Shaker-like K+ channels (Kv1.1, Kv1.3, Kv1.5) | Gene and protein upregulation | Glioma, breast cancer, lung cancer, pancreas cancer, prostate cancer, lymphoma | [ |
| EAG K+ channels (EAG1, EAG2) | Gene and protein upregulation | Medulloblastoma, breast cancer, head and neck cancer, melanoma, gastrointestinal tract cancer | [ |
| EAG-related K+ channels (HERG/Kv11.1) | Gene and protein upregulation | Melanoma, neuroblastoma, breast cancer | [ |
| Ca2+-activated K+ channels (KCa3.1) | Gene and protein upregulation | Glioma, breast cancer, ovarian cancer, prostate cancer, melanoma | [ |
| TRP (TRPC6, TRPV6, TRPM7, TRPM8) | Gene and protein upregulation | Breast cancer, prostate cancer, head and neck cancer, human glioblastoma cell line | [ |
| P2Y (P2Y2), P2X (P2X7), P2U | Gene and protein upregulation | Melanoma, colorectal cancer cells, lung cancer cells | [ |
| SOCs (ORAI1/STIM1) | Gene and protein downregulation | Lung cancer cells, cervical cancer | [ |
| SOCs (ORAI1/STIM1) | Gene and protein upregulation | Cervical cancer, glioblastoma cells | [ |
| EAG K+ channels (EAG1/ Kv10.1) | Gene and protein upregulation | Migration of breast cancer cells | [ |
| Ca2+-activated K+ channels (KCNMA1, SK3/ORAI1, KCa1.1, KCa3.1) | Gene and protein upregulation | Breast cancer→metastasis to brain Breast cancer→bone metastasis Migration of glioma cells, transformed renal epithelial cells and breast cancer cells | [ |
| Kir channels (Kir3.1/GIRK1) | Gene and protein upregulation | Primary breast cancer→axillary lymph node metastasis | [ |
| TRP (TRPM7, TRPM8, TRPV1, TRPV6) | Gene and protein upregulation | Lung cancer cells, primary breast cancer, prostate cancer cells, squamos carcinoma, hepatoblastoma | [ |
| P2X (P2X7) | Gene and protein upregulation | Breast cancer cell line | [ |
| SOCs (ORAI1/STIM1) | Gene and protein upregulation | Breast cancer, cervical cancer, hepatocarcinoma, glioblastoma | [ |
| EAG K+ channels (EAG1) | Gene and protein upregulation | Breast cancer and other solid tumors | [ |
| TRP (TRPC6 ) | Gene and protein upregulation | Human glioblastoma cell line | [ |
| SOCs (ORAI1/STIM1) | siRNA- or dominant-negative mutant-mediated knockdown | VEGF-induced angiogenesis observed in tumors | [ |
| Shaker-like K+ channels (Kv1.3) | Gene and protein upregulation | Large B-cell lymphoma, glioma | [ |
| TRP (TRPA1) | Gene and protein upregulation | Lung cancer cell line | [ |
| P2X (P2X7) | Gene and protein downregulation | Breast cancer, melanoma | [ |
| SOCs (ORAI1) | siRNA-mediated knockdown | Prostate cancer cell line | [ |
Ion channel blockers in immune and cancer cells
| Margatoxin (MgTX) Charybdotoxin (CTX) | Kv1.3 | T lymphoctyes, Jurkat cells | Antiproliferative effect in T-lymphoytes, regulation of immunoresponsiveness | [ |
| TRAM-34, NS6180, ShK-186 | Kv1.3, KCa3.1 | NK cells, leukemia cells | Inhibition of KCa3.1 increased the degranulation of adherent NK cells and their ability to kill K562 leukemia cells | [ |
| R-roscovitine | Kv1.3, Kv2.1, Kv4.2, HERG (Kv11.1) | Leukemia | Roscovitine is well known cyclin-dependent kinase inhibitor | [ |
| mAb56 | EAG1 (Kv10.1) | Pancreas carcinoma, breast cancer | Inhibition of tumor cell growth both | [ |
| Way 123,398 | HERG (Kv11.1) | Colorectal cancer | Reduced cell migration of H630, HCT and HCT8 cells; unaffected growth of HEK 293 cells | [ |
| Way 123,398; CsCl; E4031 | HERG (Kv11.1) | Acute myeloid leukemia | Impaired cell proliferation. | [ |
| Cisapride | HERG (Kv11.1) | Gastric cancer | Inhibition of cells entering S phase from G1 phase of the cell cycle. | [ |
| Verapamil | ERG (Kv11.1) | Lung cancer, melanoma, colon cancer | Increased survival rate for patients treated with verapamil+chemotherapy | [ |
| UNBS0 (Cardenolide) | Na+/K+ ATPase | Glioblastoma | Decrease in intracellular ATP concentration leads to autophagy in glioma cells
UNBS0 shows anti-proliferative activity | [ |
| Tetrodotoxin (TTX) | Nav1.5, Nav1.6 Voltage-gated Na+ channels | Human melanoma, macrophages, breast cancer | TTX and shRNA knockdown of Nav1.6 has inhibitory effects on both cellular invasion of macrophages and melanoma cells | [ |
| Charybdotoxin (CTX) | Kir (IK1) | Human melanoma | Reduced migration of melanoma cells treated with CTX | [ |
| Zinc, methanandamide | K2P9.1 (TASK-3) | Ovarian cancer | Reduction in cell proliferation and increase in apoptosis | [ |
Figure 2The influence of ion channels on the interaction between the immune system and cancer as well as their role in neoplastic transformation